{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:41:54Z","timestamp":1790138514138,"version":"4.0.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","ajkd.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.ajkd.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:59:39Z","timestamp":1735631979000},"page":"421-431.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of Statins for Primary Prevention Among Individuals With CKD in the United States: A Cross-Sectional, Time-Trend Analysis"],"prefix":"10.1053","volume":"85","author":[{"given":"Oshozimhede E.","family":"Iyalomhe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarasinghe Arachchige Don Nalin Samandika","family":"Saparamadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2020.10.004","article-title":"Chronic kidney disease and statin eligibility","volume":"15","author":"Vega","year":"2021","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1053\/j.ajkd.2024.11.003_bib2","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.54","article-title":"Cardiovascular complications of chronic kidney disease: an introduction","volume":"17","author":"Warrens","year":"2022","journal-title":"Eur Cardiol"},{"issue":"11","key":"10.1053\/j.ajkd.2024.11.003_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2024.11.003_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4842699","article-title":"Statins have an anti-inflammation in CKD patients: a meta-analysis of randomized trials","volume":"2022","author":"Wang","year":"2022","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.003_bib5","article-title":"Trends in statin use among US adults with chronic kidney disease, 1999-2014","volume":"8","author":"Mefford","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.003_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ckj\/sfy131","article-title":"Low statin use in nondialysis-dependent chronic kidney disease in the absence of clinical atherosclerotic cardiovascular disease or diabetes","volume":"12","author":"Markossian","year":"2019","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.ajkd.2024.11.003_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1053\/j.ajkd.2013.11.014","article-title":"Potential effects of reclassifying CKD as a coronary heart disease risk equivalent in the us population","volume":"63","author":"Foster","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2024.11.003_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2014.02.001","article-title":"Lipid-lowering guidelines and statin use in CKD: a time for change","volume":"63","author":"Baber","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.003_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2014.10.005","article-title":"KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD","volume":"65","author":"Sarnak","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.11.003_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2024.11.003_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bcpt.13768","article-title":"Statin use before and after the KDIGO lipids in chronic kidney disease guideline: a population-based interrupted time series analysis","volume":"131","author":"Kampmann","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"10.1053\/j.ajkd.2024.11.003_bib12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc22-1253","article-title":"Pharmacologic treatment of type 2 diabetes in the U.S., Sweden, and Israel","volume":"45","author":"Lyu","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.003_bib13","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1042","article-title":"Prescription medication use among children and adolescents in the United States","volume":"142","author":"Qato","year":"2018","journal-title":"Pediatrics"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.003_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.ajkd.2012.09.013","article-title":"Calibration of cystatin C in the National Health and Nutrition Examination Surveys","volume":"61","author":"Selvin","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1053\/j.ajkd.2024.11.003_bib16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2024.11.003_bib18","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.003_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27014","article-title":"Trends in chronic kidney disease care in the US by race and ethnicity, 2012-2019","volume":"4","author":"Chu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1053\/j.ajkd.2024.11.003_bib21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC\/AHA guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1053\/j.ajkd.2024.11.003_bib22","author":"Rakshit"},{"issue":"22","key":"10.1053\/j.ajkd.2024.11.003_bib23","first-page":"6984","article-title":"Cardiovascular disease in diabetes and chronic kidney disease","volume":"12","author":"Swamy","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.003_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4212\/cjhp.v74i3.3149","article-title":"Evaluation of statin use and prescribing in patients with chronic kidney disease not receiving treatment with kidney transplant or dialysis","volume":"74","author":"Wu","year":"2021","journal-title":"Can J Hosp Pharm"},{"issue":"2","key":"10.1053\/j.ajkd.2024.11.003_bib25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCOUTCOMES.113.000769","article-title":"How Do the 2013 cholesterol guidelines compare with previous cholesterol guideline reports?","volume":"7","author":"Jackevicius","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9","key":"10.1053\/j.ajkd.2024.11.003_bib26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjmed.2016.04.012","article-title":"Lipid management guidelines from the Departments of Veteran Affairs and Defense: a critique","volume":"129","author":"Bennet","year":"2016","journal-title":"Am J Med"},{"issue":"15","key":"10.1053\/j.ajkd.2024.11.003_bib27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.282.15.1458","article-title":"Why don\u2019t physicians follow clinical practice guidelines? A framework for improvement","volume":"282","author":"Cabana","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2024.11.003_bib28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/gfac283","article-title":"Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease","volume":"38","author":"Nee","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-020-00559-7","article-title":"Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review","volume":"12","author":"Andreozzi","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-15-64","article-title":"Primary care physicians\u2019 familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study","volume":"15","author":"Abdel-Kader","year":"2014","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2024.11.003_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MOL.0000000000000835","article-title":"Translating guidelines into practice via implementation science: an update in lipidology","volume":"33","author":"Jones","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1053\/j.ajkd.2024.11.003_bib33","author":"Rosenstein"},{"issue":"4","key":"10.1053\/j.ajkd.2024.11.003_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/ckj\/sfx140","article-title":"Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research","volume":"11","author":"Nielsen","year":"2018","journal-title":"Clin Kidney J"},{"issue":"7","key":"10.1053\/j.ajkd.2024.11.003_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7932","article-title":"National trends in the prevalence of chronic kidney disease among racial\/ethnic and socioeconomic status groups, 1988-2016","volume":"3","author":"Vart","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1053\/j.ajkd.2024.11.003_bib36","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed Res Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624011272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638624011272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T18:28:08Z","timestamp":1742668088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638624011272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0272638624011272"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.003","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Statins for Primary Prevention Among Individuals With CKD in the United States: A Cross-Sectional, Time-Trend Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}